Birkett Ashley J
PATH Malaria Vaccine Initiative (MVI), 455 Massachusetts Avenue NW, Suite 1000, Washington, DC 20001-2621, USA.
Vaccine. 2015 Dec 22;33(52):7538-43. doi: 10.1016/j.vaccine.2015.09.111. Epub 2015 Oct 19.
Despite impressive gains over the last 15 years in reducing the mortality associated with malaria, it remains a public health emergency. New interventions, such as vaccines, are needed to ensure that previous gains serve as a foundation for future progress. Vaccines have the potential to prevent severe disease and death in those most vulnerable, and to accelerate elimination and eradication by breaking the cycle of parasite transmission. The pipeline is as healthy as it has ever been, with approaches targeting different stages of the parasite lifecycle using an array of technologies. This article reviews recent progress and reviews key considerations in the quest to develop products that are aligned with the unmet medical need.
尽管在过去15年里，在降低疟疾相关死亡率方面取得了令人瞩目的成绩，但疟疾仍然是一个突发公共卫生事件。需要新的干预措施，如疫苗，以确保之前取得的成果成为未来进展的基础。疫苗有潜力预防最脆弱人群的严重疾病和死亡，并通过打破寄生虫传播循环来加速疟疾的消除和根除。目前的研发进展良好，有一系列技术针对寄生虫生命周期的不同阶段。本文回顾了近期进展，并探讨了在开发满足未被满足的医疗需求的产品过程中的关键考量因素。
